NASDAQ:ACRV Acrivon Therapeutics (ACRV) Stock Price, News & Analysis → War Over Taiwan? Protect Your Wealth NOW (From Behind the Markets) (Ad) Free ACRV Stock Alerts $8.57 +0.10 (+1.18%) (As of 01:02 PM ET) Add Compare Share Share Today's Range$8.31▼$8.7850-Day Range$3.76▼$10.5452-Week Range$3.19▼$14.30Volume111,392 shsAverage Volume602,186 shsMarket Capitalization$194.02 millionP/E RatioN/ADividend YieldN/APrice Target$21.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Acrivon Therapeutics alerts: Email Address Acrivon Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside154.1% Upside$21.75 Price TargetShort InterestHealthy4.98% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.32Based on 13 Articles This WeekInsider TradingAcquiring Shares$20 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($3.30) to ($3.13) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.82 out of 5 starsMedical Sector212th out of 908 stocksPharmaceutical Preparations Industry86th out of 424 stocks 4.5 Analyst's Opinion Consensus RatingAcrivon Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAcrivon Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.98% of the float of Acrivon Therapeutics has been sold short.Short Interest Ratio / Days to CoverAcrivon Therapeutics has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Acrivon Therapeutics has recently increased by 93.25%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAcrivon Therapeutics does not currently pay a dividend.Dividend GrowthAcrivon Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ACRV. Previous Next 3.0 News and Social Media Coverage News SentimentAcrivon Therapeutics has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Acrivon Therapeutics this week, compared to 1 article on an average week.Search Interest2 people have searched for ACRV on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows9 people have added Acrivon Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 800% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Acrivon Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $20,000,500.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 7.30% of the stock of Acrivon Therapeutics is held by insiders.Percentage Held by Institutions71.62% of the stock of Acrivon Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Acrivon Therapeutics are expected to grow in the coming year, from ($3.30) to ($3.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Acrivon Therapeutics is -3.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Acrivon Therapeutics is -3.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAcrivon Therapeutics has a P/B Ratio of 1.57. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsWar Over Taiwan? Protect Your Wealth NOWWith tensions rapidly escalating, Taiwan could provide the spark at any moment. Don't let your financial future get caught in the crossfire unprepared.Access my report now >>> About Acrivon Therapeutics Stock (NASDAQ:ACRV)Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.Read More ACRV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACRV Stock News HeadlinesApril 16, 2024 | insidertrades.comAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Major Shareholder Buys $20,000,500.00 in StockApril 25, 2024 | markets.businessinsider.comAcrivon Therapeutics: Strong Buy Recommendation on Impressive AP3 Platform and ACR-368 Data ValidationApril 26, 2024 | Behind the Markets (Ad)War Over Taiwan? Protect Your Wealth NOWWith tensions rapidly escalating, Taiwan could provide the spark at any moment. Don't let your financial future get caught in the crossfire unprepared.April 25, 2024 | markets.businessinsider.comAcrivon Therapeutics: Strong Buy on Impressive Clinical Outcomes and Market PotentialApril 24, 2024 | msn.comAcrivon Therapeutics’ shares climb 14% on plans to present cancer-test dataApril 24, 2024 | globenewswire.comAcrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D EventApril 20, 2024 | finance.yahoo.comAcrivon Therapeutics, Inc. (ACRV)April 20, 2024 | americanbankingnews.comAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Given Average Recommendation of "Buy" by BrokeragesApril 26, 2024 | Behind the Markets (Ad)War Over Taiwan? Protect Your Wealth NOWWith tensions rapidly escalating, Taiwan could provide the spark at any moment. Don't let your financial future get caught in the crossfire unprepared.April 16, 2024 | finance.yahoo.comAcrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316April 16, 2024 | americanbankingnews.comAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Sees Significant Increase in Short InterestApril 16, 2024 | americanbankingnews.comAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Major Shareholder Perceptive Advisors Llc Buys 2,353,000 SharesApril 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Acrivon Therapeutics on Promising Drug Pipeline and Solid FinancialsApril 10, 2024 | globenewswire.comAcrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistance Mechanisms to ACR-368April 9, 2024 | markets.businessinsider.comAcrivon To Privately Place $130 Mln Of Shares; Stock Soars In Pre-marketApril 9, 2024 | msn.comAcrivon Therapeutics Stock Is Soaring Tuesday: What's Going On?April 9, 2024 | investorplace.comACRV Stock Jumps 55% as Acrivon Therapeutics Gets $130 Million BoostApril 9, 2024 | globenewswire.comAcrivon Therapeutics Announces $130 Million Private Placement FinancingApril 1, 2024 | markets.businessinsider.comBuy Rating on Acrivon Therapeutics: Anticipated Clinical Validation and Strong Financial PositionMarch 29, 2024 | markets.businessinsider.comBuy Rating Affirmed for Acrivon Therapeutics Amid Anticipated Clinical Updates and Platform PotentialMarch 29, 2024 | markets.businessinsider.comBuy Rating Justified by Acrivon Therapeutics’ Clinical Progress and Market PotentialMarch 29, 2024 | markets.businessinsider.comAcrivon Therapeutics: Strong Buy on Promising Clinical Trials and Innovative Drug DevelopmentMarch 28, 2024 | investorplace.comACRV Stock Earnings: Acrivon Therapeutics Misses EPS for Q4 2023March 28, 2024 | finanznachrichten.deAcrivon Therapeutics, Inc: Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business HighlightsMarch 28, 2024 | benzinga.comAcrivon Therapeutics: Q4 Earnings InsightsMarch 28, 2024 | globenewswire.comAcrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business HighlightsMarch 5, 2024 | globenewswire.comAcrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316See More Headlines Receive ACRV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acrivon Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2024Today4/26/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ACRV CUSIPN/A CIK1781174 Webwww.acrivon.com Phone617-207-8979FaxN/AEmployees58Year FoundedN/APrice Target and Rating Average Stock Price Target$21.75 High Stock Price Target$30.00 Low Stock Price Target$14.00 Potential Upside/Downside+155.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($2.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-60,390,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-42.45% Return on Assets-38.99% Debt Debt-to-Equity RatioN/A Current Ratio9.75 Quick Ratio9.75 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.46 per share Price / Book1.56Miscellaneous Outstanding Shares22,640,000Free Float20,984,000Market Cap$193.12 million OptionableNot Optionable Beta1.94 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Peter Blume-Jensen M.D. (Age 61)Ph.D., Co-Founder, Chairman of the Board, CEO, President & Acting Chief Scientific Officer Comp: $1.01MMs. Kristina Masson M.B.A. (Age 43)Ph.D., Co-Founder, Executive VP of Business Operations, Site Head, Treasurer, Secretary & Director Mr. Rasmus Holm-Jorgensen (Age 53)Chief Financial Officer Comp: $1MDr. Eric J. Devroe Ph.D. (Age 46)Chief Operating Officer Comp: $614.78kMs. Katharine Peterson CPAVice President of Finance & AccountingDr. Adam D. Levy M.B.A.Ph.D., Senior VP and Head of Investor Relations & Corporate AffairsMr. Bruce CloseVice President of Quality & ComplianceMs. Mary-Alice Miller J.D. (Age 50)Chief Legal Officer Ms. Parvin MiahVP & Head of Human ResourcesDr. Erick Gamelin M.D. (Age 66)Ph.D., Chief Development Officer Comp: $480.72kMore ExecutivesKey CompetitorsImmutepNASDAQ:IMMPFoghorn TherapeuticsNASDAQ:FHTXG1 TherapeuticsNASDAQ:GTHXOvid TherapeuticsNASDAQ:OVIDuniQureNASDAQ:QUREView All CompetitorsInsidersPerceptive Advisors LlcBought 2,353,000 shares on 4/11/2024Total: $20.00 M ($8.50/share)Ltd ChioneSold 16 sharesTotal: $206.88 ($12.93/share)Ltd ChioneSold 893 sharesTotal: $10,832.09 ($12.13/share)Ltd ChioneSold 2,000 sharesTotal: $24,680.00 ($12.34/share)View All Insider Transactions ACRV Stock Analysis - Frequently Asked Questions Should I buy or sell Acrivon Therapeutics stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Acrivon Therapeutics in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ACRV shares. View ACRV analyst ratings or view top-rated stocks. What is Acrivon Therapeutics' stock price target for 2024? 8 brokers have issued twelve-month price targets for Acrivon Therapeutics' shares. Their ACRV share price targets range from $14.00 to $30.00. On average, they anticipate the company's share price to reach $21.75 in the next twelve months. This suggests a possible upside of 154.1% from the stock's current price. View analysts price targets for ACRV or view top-rated stocks among Wall Street analysts. How have ACRV shares performed in 2024? Acrivon Therapeutics' stock was trading at $4.92 at the beginning of the year. Since then, ACRV stock has increased by 74.0% and is now trading at $8.56. View the best growth stocks for 2024 here. Are investors shorting Acrivon Therapeutics? Acrivon Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 533,000 shares, an increase of 10.1% from the March 15th total of 484,000 shares. Based on an average daily trading volume, of 661,100 shares, the days-to-cover ratio is presently 0.8 days. Approximately 4.4% of the shares of the stock are sold short. View Acrivon Therapeutics' Short Interest. When is Acrivon Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our ACRV earnings forecast. How were Acrivon Therapeutics' earnings last quarter? Acrivon Therapeutics, Inc. (NASDAQ:ACRV) released its quarterly earnings results on Thursday, March, 28th. The company reported ($0.86) EPS for the quarter, missing the consensus estimate of ($0.72) by $0.14. What ETFs hold Acrivon Therapeutics' stock? ETFs with the largest weight of Acrivon Therapeutics (NASDAQ:ACRV) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Loncar China Biopharma ETF (CHNA). When did Acrivon Therapeutics IPO? Acrivon Therapeutics (ACRV) raised $100 million in an initial public offering (IPO) on Tuesday, November 15th 2022. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Jefferies, Cowen and Piper Sandler served as the underwriters for the IPO. How do I buy shares of Acrivon Therapeutics? Shares of ACRV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ACRV) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold GroupEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acrivon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
